Several experimental in vitro and in vivo studies as well as clinical trials revealed that the KEAP1-Nrf2 pathway as well as its downstream mediators has been recognized as key players in the evolution of ALS. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.